These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 9288768)

  • 41. Study of FHIT transcripts in normal and malignant breast tissue.
    Bièche I; Latil A; Becette V; Lidereau R
    Genes Chromosomes Cancer; 1998 Dec; 23(4):292-9. PubMed ID: 9824201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concordant loss of fragile gene expression early in breast cancer development.
    Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
    Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.
    Fullwood P; Marchini S; Rader JS; Martinez A; Macartney D; Broggini M; Morelli C; Barbanti-Brodano G; Maher ER; Latif F
    Cancer Res; 1999 Sep; 59(18):4662-7. PubMed ID: 10493522
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumors.
    Kholodnyuk ID; Szeles A; Yang Y; Klein G; Imreh S
    Cancer Res; 2000 Dec; 60(24):7119-25. PubMed ID: 11156420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The murine Fhit gene is highly similar to its human orthologue and maps to a common fragile site region.
    Glover TW; Hoge AW; Miller DE; Ascara-Wilke JE; Adam AN; Dagenais SL; Wilke CM; Dierick HA; Beer DG
    Cancer Res; 1998 Aug; 58(15):3409-14. PubMed ID: 9699673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas.
    Lee SH; Kim WH; Kim HK; Woo KM; Nam HS; Kim HS; Kim JG; Cho MH
    Biochem Biophys Res Commun; 2001 Jun; 284(3):850-5. PubMed ID: 11396980
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line.
    Futreal PA; Cochran C; Marks JR; Iglehart JD; Zimmerman W; Barrett JC; Wiseman RW
    Cancer Res; 1994 Apr; 54(7):1791-4. PubMed ID: 7511052
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Association of fragile histidine triad gene (FHIT) with susceptibility to esophageal cancer. A preliminary study].
    Li W; Wang X; Cheng G
    Zhonghua Zhong Liu Za Zhi; 1998 Jul; 20(4):258-60. PubMed ID: 10920977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
    J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development.
    Lea JS; Ashfaq R; Muneer S; Burbee DG; Miller DS; Minna JD; Muller CY
    J Soc Gynecol Investig; 2004 Jul; 11(5):329-37. PubMed ID: 15219888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease.
    Campiglio M; Pekarsky Y; Menard S; Tagliabue E; Pilotti S; Croce CM
    Cancer Res; 1999 Aug; 59(16):3866-9. PubMed ID: 10463571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
    Ishii H; Vecchione A; Furukawa Y; Sutheesophon K; Han SY; Druck T; Kuroki T; Trapasso F; Nishimura M; Saito Y; Ozawa K; Croce CM; Huebner K; Furukawa Y
    Mol Cancer Res; 2003 Nov; 1(13):940-7. PubMed ID: 14638866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.
    Turner BC; Ottey M; Zimonjic DB; Potoczek M; Hauck WW; Pequignot E; Keck-Waggoner CL; Sevignani C; Aldaz CM; McCue PA; Palazzo J; Huebner K; Popescu NC
    Cancer Res; 2002 Jul; 62(14):4054-60. PubMed ID: 12124341
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Loss of FHIT expression in gastric carcinoma.
    Baffa R; Veronese ML; Santoro R; Mandes B; Palazzo JP; Rugge M; Santoro E; Croce CM; Huebner K
    Cancer Res; 1998 Oct; 58(20):4708-14. PubMed ID: 9788626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative genomic mapping of the bovine Fragile Histidine Triad (FHIT) tumour suppressor gene: characterization of a 2 Mb BAC contig covering the locus, complete annotation of the gene, analysis of cDNA and of physiological expression profiles.
    Uboldi C; Guidi E; Roperto S; Russo V; Roperto F; Di Meo GP; Iannuzzi L; Floriot S; Boussaha M; Eggen A; Ferretti L
    BMC Genomics; 2006 May; 7():123. PubMed ID: 16719907
    [TBL] [Abstract][Full Text] [Related]  

  • 56. p27/Kip1 mutation found in breast cancer.
    Spirin KS; Simpson JF; Takeuchi S; Kawamata N; Miller CW; Koeffler HP
    Cancer Res; 1996 May; 56(10):2400-4. PubMed ID: 8625318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fragile histidine triad transcription abnormalities and human papillomavirus E6-E7 mRNA expression in the development of cervical carcinoma.
    Segawa T; Sasagawa T; Yamazaki H; Sakaike J; Ishikawa H; Inoue M
    Cancer; 1999 May; 85(9):2001-10. PubMed ID: 10223242
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FHIT alterations in breast cancer.
    Ingvarsson S
    Semin Cancer Biol; 2001 Oct; 11(5):361-6. PubMed ID: 11562178
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis.
    Gramantieri L; Chieco P; Di Tomaso M; Masi L; Piscaglia F; Brillanti S; Gaiani S; Valgimigli M; Mazziotti A; Bolondi L
    Clin Cancer Res; 1999 Nov; 5(11):3468-75. PubMed ID: 10589760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
    Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
    Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.